Combo Products Will Grow More Dependent On Drug Function – Guidant Exec
This article was originally published in The Gray Sheet
Executive Summary
Product stability, drug release rates and other factors unique to pharmaceuticals will grow increasingly relevant to device firms developing combination products, according to Guidant VP-Endovascular Operations Richard Rapoza, PhD